Advertisement

Gastro-News

, Volume 6, Issue 2, pp 34–42 | Cite as

Hepatologie — Teil 2: Hepatozelluläres Karzinom

Neue lokale und systemische Therapieoptionen beim HCC

  • Michael SchultheißEmail author
  • Robert Thimme
zertifizierte fortbildung
  • 217 Downloads

Zusammenfassung

Das hepatozelluläre Karzinom ist weltweit die sechsthäufigste Tumorentität — mit steigender Inzidenz in der westlichen Welt. Da nur in frühen Stadien eine kurative Therapie möglich ist, hat die Früherkennung für die Prognose eine entscheidende Bedeutung. Für alle Patienten mit dem Risiko für ein hepatozelluläres Karzinom wird daher eine Abdomensonografie alle sechs Monate empfohlen. Zur Therapie des hepatozellulären Karzinoms gibt es verschiedene lokale Behandlungsoptionen, systemische Therapien sind bisher aber noch limitiert.

Literatur

  1. 1.
    European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2018; 69: 182-236Google Scholar
  2. 2.
    Greten TF, Malek NP, Schmidt S et al. Diagnosis of and therapy for hepatocellular carcinoma. Z Gastroenterol 2013; 51: 1269–1326CrossRefGoogle Scholar
  3. 3.
    Livraghi T, Meloni F, Di Stasi M et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice? Hepatology 2008; 47: 82–89CrossRefGoogle Scholar
  4. 4.
    Roayaie S, Obeidat K, Sposito C et al. Resection of hepatocellular cancer.2 cm: results from two Western centers. Hepatology 2013; 57: 1426–1435CrossRefGoogle Scholar
  5. 5.
    Yoon YI, Kim KH, Kang SH et al. Laparoscopic versus open right hepatectomy for hepatocellular carcinoma in patients with cirrhosis: a propensity score matched analysis. Ann Surg 2017; 265: 856–863CrossRefGoogle Scholar
  6. 6.
    Nadalin S, Capobianco I, Li J et al. Indications and limits for associating liver partition and portal vein ligation for staged hepatectomy (ALPPS). Lessons learned form 15 cases at a single centre. Z Gastroenterol 2014; 52: 35–42CrossRefGoogle Scholar
  7. 7.
    Richtlinien zur Organtransplantation gem. §16 TPG. Deutsches Arzteblatt 2015; DOI: 10.3238/arzteblGoogle Scholar
  8. 8.
    Vilgrain V, Pereira H, Assenat E et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol 2017; 18: 1624–1636CrossRefGoogle Scholar
  9. 9.
    Chow PHW, Gandhi M, Group A-PHCT. Phase III multi-centre open-label randomized controlled trial of selective internal radiation therapy (SIRT) versus sorafenib in locally advanced hepatocellular carcinoma: The SIRveNIB study. Journal of Clinical Oncology 2017; 35: 4002CrossRefGoogle Scholar
  10. 10.
    Bujold A, Massey CA, Kim JJ et al. Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol 2013; 31: 1631–1639CrossRefGoogle Scholar
  11. 11.
    Gkika E, Schultheiss M, Bettinger D et al. Excellent local control and tolerance profile after stereotactic body radiotherapy of advanced hepatocellular carcinoma. Radiat Oncol 2017; 12: 116CrossRefGoogle Scholar
  12. 12.
    Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 2008; 359: 378–390Google Scholar
  13. 13.
    Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a Phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009; 10: 25–34CrossRefGoogle Scholar
  14. 14.
    Bruix J, Qin S, Merle P et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017; 389: 56–66CrossRefGoogle Scholar
  15. 15.
    Kudo M, Finn RS, Qin S et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomized phase 3 non-inferiority trial. Lancet 2018; 391: 1163–1173CrossRefGoogle Scholar
  16. 16.
    Abou-Alfa GK, Meyer T, Cheng AL et al. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med 2018; 379: 54–63CrossRefGoogle Scholar
  17. 17.
    Zhu AX, Kang YK, Yen CJ et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concetrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol, 2019; 20: 282–296CrossRefGoogle Scholar
  18. 18.
    El-Khoueiry AB, Sangro B, Yau T et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017; 389: 2492–2502CrossRefGoogle Scholar
  19. 19.
    Zhu AX, Finn RS, Edeline J et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol 2018; 19: 940–952CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2019

Authors and Affiliations

  1. 1.Klinik für Innere Medizin IIUniversitätsklinikum Freiburg, Medizinische Fakultät, Albert-Ludwigs-Universität FreiburgFreiburgDeutschland

Personalised recommendations